COMMUNIQUÉS West-GlobeNewswire

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
07/05/2026
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median [...]
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
07/05/2026
Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to [...]
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
07/05/2026
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. ( [...]
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
07/05/2026
Interim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin in the second [...]
Nephros Announces Financial Results for Quarter Ended March 31, 2026
07/05/2026
First-Quarter Net Revenue Growth of 7% to $5.2 million; Core Programmatic Revenue Grew by 23% Year Over Year SOUTH ORANGE, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology [...]
Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
07/05/2026
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
07/05/2026
CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis [...]
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
07/05/2026
4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 4FRONT - 2 enrollment completion expected in H2 2026; topline data expected in H2 2027 4D-150 PRISM wet AMD Phase 2b 2- [...]
LeMaitre to Present at the Bank of America Healthcare Conference
07/05/2026
BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced today that management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM [...]
Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call
07/05/2026
ROSELAND, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05/2026
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, [...]
Tarsus to Participate in Upcoming Investor Conferences
07/05/2026
IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Bank of America [...]
NetraMark Announces Change To Board Of Directors
07/05/2026
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials [...]
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
07/05/2026
SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancers SIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 [...]
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
07/05/2026
Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges Early BEST1 Data Show Visual Acuity Gains and Improved Retinal [...]
BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026
08/05/2026
MISSISSAUGA, Ontario, May 07, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the first quarter ended March 31, 2026 on Thursday, May 14, [...]
SK pharmteco collabore avec Axle Informatics et les Instituts nationaux de la santé afin de développer des programmes de thérapie génique pour les maladies rares
07/05/2026
RANCHO CORDOVA, Californie, 07 mai 2026 (GLOBE NEWSWIRE) -- SK pharmteco a annoncé ce jour un partenariat stratégique avec Axle Informatics et les Instituts nationaux de la santé (NIH) en vue de promouvoir le [...]
The Helios Alliance Applauds Dr. Rahul Gupta's Appointment to Knoa Foundation Board of Trustees
07/05/2026
Leadership team member brings national expertise to oversight of pharmaceutical company emerging from Purdue Pharma settlement, advancing transparency and accountability in opioid abatement nationwide Mobile, ALABAMA, [...]
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
07/05/2026
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety [...]

Pages